Prostate CancerMore Choices in PSA Tests

Each year almost 700,000 new cases of prostate cancer are diagnosed worldwide, and approximately 221,000 deaths occur annually due to prostate cancer. Siemens Healthcare Diagnostics offers a full menu of Prostate Specific Antigen (PSA) tests that aid in the detection, monitoring and management of prostate cancer. In addition to traditional PSA tests, the Siemens portfolio of PSA assays includes unique Complexed PSA and Third Generation PSA assays that are alternatives to conventional testing.

Laboratorians

Siemens can equip your cancer center, hospital, or reference laboratory with the full menu of in vitro PSA tests demanded by today’s healthcare professionals, including Complexed PSA and 3rd Generation PSA assays that are alternatives to traditional PSA tests. The Siemens portfolio of PSA assays provides your healthcare clients with more choices to aid in prostate cancer detection, monitoring, and follow-up.
 

The Siemens Portfolio of PSA Assays

PSA tests run on ADVIA Centaur®, IMMULITE® and Dimension® systems ensure cost-effectiveness and fast turnaround times.
 

Dimension Vista®

PSA
PSA
PSA
PSA
PSA
PSA
PSA

fPSA1

fPSA1

fPSA

fPSA

fPSA

fPSA

fPSA

Complexed PSA

Complexed PSA

Third Generation PSA

-

-

-

-

PSA Test

PSA testing is clinically accepted by the NACB and EGTM for both detection and monitoring.1

  • Quantitatively measures prostate specific antigen in serum
  • Classic screening method to aid in the detection of prostate cancer
  • Used in conjunction with a digital rectal examination (DRE)

 

3rd Generation PSA Test2

Our 3rd Generation PSA assay aids in the detection of prostate cancer and is used as an adjunctive test to aid in the management of prostate cancer patients.

  • Provides information on possible relapse in facilitating patient management
  • Provides an early indication of disease status after treatment when used in conjunction with other clinical information3
  • Approved for prostate cancer detection in conjunction with a digital rectal examination (DRE)

 

Free PSA Test

Our fPSA assay helps guide decision-making in men aged 50 years or older who have DRE findings not suspicious of cancer who are in the diagnostic gray zone (4.0–10 ng/mL).

  • Percent free PSA assessment may help to reduce unnecessary biopsies4,5
  • It helps to differentiate cancer from benign prostatic hyperplasia
  • Percent free PSA is lower in prostate cancer than in benign prostate hyperplasia4,5

 

Complexed PSA Test

The Siemens proprietary Complexed PSA is an alternative to traditional PSA testing for frontline detection.

  • PSA complexed with alpha-1-antichymotrypsin (ACT) comprises a higher proportion of PSA in men with prostate cancer6-8
  • It is recommended as a frontline detection test
  • It is used in conjunction with a digital rectal examination (DRE)
     

System

Assay

Reportable Range

PSA

0.01 ng/mL - 100 ng/mL

 

Complexed PSA

0.03 ng/mL - 100 ng/mL

 

FPSA*

0.01 ng/mL - 25 ng/mL

PSA

0.04 ng/mL - 150 ng/mL

 

FPSA

0.07 ng/mL - 25 ng/mL

 

3rd Generation PSA**

0.005 ng/mL - 20 ng/mL

PSA

0.13 ng/mL - 100 ng/mL

 

FPSA

0.06 ng/mL - 45 ng/mL

PSA

0.010 ng/mL - 100 ng/mL

 

FPSA

0.015 ng/mL - 20 ng/mL

1
2
3
4
5
6
7
8
Subscription Button Icon
Be the first to know about our events, training, and news